• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹膜透析患者的血管及其他组织钙化

Vascular and other tissue calcification in peritoneal dialysis patients.

作者信息

Wang Angela Yee-Moon

机构信息

University Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, PR China.

出版信息

Perit Dial Int. 2009 Feb;29 Suppl 2:S9-S14.

PMID:19270239
Abstract

Cardiovascular disease is the leading cause of mortality in patients with end-stage renal disease (ESRD) and is attributed to a combination of traditional and non-traditional cardiovascular risk factors. In recent years, there has also been an increasing recognition of a very high prevalence of cardiovascular calcification in the ESRD population, including in patients receiving long-term peritoneal dialysis (PD). Numerous observational cohort studies have demonstrated the prognostic importance of cardiovascular calcifications in these patients. The mechanisms are not completely understood, but are likely multifactorial. The present article reviews the prevalence, clinical course, prognostic significance, and some contributing factors for vascular and valvular calcification in ESRD patients, including patients receiving PD therapy.

摘要

心血管疾病是终末期肾病(ESRD)患者死亡的主要原因,这归因于传统和非传统心血管危险因素的综合作用。近年来,人们也越来越认识到ESRD人群中,包括接受长期腹膜透析(PD)的患者,心血管钙化的患病率非常高。大量观察性队列研究已经证明了心血管钙化在这些患者中的预后重要性。其机制尚未完全了解,但可能是多因素的。本文综述了ESRD患者,包括接受PD治疗的患者,血管和瓣膜钙化的患病率、临床过程、预后意义以及一些促成因素。

相似文献

1
Vascular and other tissue calcification in peritoneal dialysis patients.腹膜透析患者的血管及其他组织钙化
Perit Dial Int. 2009 Feb;29 Suppl 2:S9-S14.
2
The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis.循环钙化抑制剂胎球蛋白-A和骨保护素,而非基质Gla蛋白,与接受透析治疗的儿童的血管僵硬和钙化有关。
Nephrol Dial Transplant. 2008 Oct;23(10):3263-71. doi: 10.1093/ndt/gfn226. Epub 2008 May 7.
3
Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients.血清胎球蛋白-A与腹膜透析患者营养不良、炎症、动脉粥样硬化及瓣膜钙化综合征的关联及预后
Nephrol Dial Transplant. 2005 Aug;20(8):1676-85. doi: 10.1093/ndt/gfh891. Epub 2005 May 17.
4
Serum levels of calcification inhibition proteins and coronary artery calcium score: comparison between transplantation and dialysis.血清钙化抑制蛋白水平与冠状动脉钙化积分:移植与透析的比较
Am J Nephrol. 2007;27(1):75-83. doi: 10.1159/000099095. Epub 2007 Jan 26.
5
Novel insights into uremic vascular calcification: role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin.对尿毒症血管钙化的新见解:基质Gla蛋白和α-2-赫曼斯-施密德糖蛋白/胎球蛋白的作用
Blood Purif. 2002;20(5):473-6. doi: 10.1159/000063554.
6
Calcification inhibitors in vascular calciphylaxis associated with normal renal function.
Thromb Haemost. 2012 Dec;108(6):1241-3. doi: 10.1160/TH12-07-0484. Epub 2012 Oct 23.
7
Consequences of chronic inflammation in peritoneal dialysis.慢性炎症对腹膜透析的影响。
Semin Nephrol. 2011 Mar;31(2):159-71. doi: 10.1016/j.semnephrol.2011.01.005.
8
Hypervolemia, hypoalbuminemia and mitral calcification as markers of cardiovascular risk in peritoneal dialysis patients.高血容量、低白蛋白血症和二尖瓣钙化作为腹膜透析患者心血管风险的标志物。
Rev Port Cardiol. 2017 Sep;36(9):599-604. doi: 10.1016/j.repc.2016.12.014. Epub 2017 Aug 23.
9
Valvular calcification and left ventricular modifying in peritoneal dialysis patients.腹膜透析患者的瓣膜钙化与左心室改变
Ren Fail. 2015;37(8):1316-22. doi: 10.3109/0886022X.2015.1073495. Epub 2015 Aug 14.
10
Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification.除血管钙化外,骨保护素升高与4期和5期慢性肾脏病患者的全因死亡率相关。
Nephrol Dial Transplant. 2009 Oct;24(10):3157-62. doi: 10.1093/ndt/gfp253. Epub 2009 Jun 2.

引用本文的文献

1
An insight investigation to the antiurolithic activity of Trachyspermum ammi using the in vitro and in vivo experiments.利用体外和体内实验对孜然芹抗尿路结石活性进行的深入研究。
Urolithiasis. 2023 Mar 3;51(1):43. doi: 10.1007/s00240-023-01415-9.
2
Epidemiology of peritoneal dialysis outcomes.腹膜透析结局的流行病学。
Nat Rev Nephrol. 2022 Dec;18(12):779-793. doi: 10.1038/s41581-022-00623-7. Epub 2022 Sep 16.
3
The association between cardiac valvular calcification and fetuin-A levels in kidney transplant recipients.心脏瓣膜钙化与肾移植受者胎球蛋白-A 水平的关系。
Clin Exp Nephrol. 2019 Oct;23(10):1250-1256. doi: 10.1007/s10157-019-01761-2. Epub 2019 Jun 27.
4
Biomarkers Associated with Vascular Calcification in Peritoneal Dialysis.与腹膜透析血管钙化相关的生物标志物
Perit Dial Int. 2016 May-Jun;36(3):262-8. doi: 10.3747/pdi.2014.00250. Epub 2015 Aug 20.
5
Coronary Artery Calcification Score as A Predictor of All-Cause Mortality and Cardiovascular Outcome in Peritoneal Dialysis Patients.冠状动脉钙化评分作为腹膜透析患者全因死亡率和心血管结局的预测指标
Perit Dial Int. 2016 Mar-Apr;36(2):163-70. doi: 10.3747/pdi.2014.00124. Epub 2015 Jul 29.
6
Mortality rates do not differ among patients prescribed various vitamin D agents.在使用不同维生素D制剂的患者中,死亡率并无差异。
Perit Dial Int. 2015 Jan-Feb;35(1):62-9. doi: 10.3747/pdi.2012.00324. Epub 2014 Mar 1.
7
Is residual renal function and better phosphate control in peritoneal dialysis an answer for the lower prevalence of valve calcification compared to hemodialysis patients?与血液透析患者相比,腹膜透析患者的残余肾功能和更好的磷酸盐控制是否是导致瓣膜钙化发生率较低的原因?
Int Urol Nephrol. 2014 Jan;46(1):175-82. doi: 10.1007/s11255-013-0438-7. Epub 2013 Apr 17.
8
The prognostic value of abdominal aortic calcification in peritoneal dialysis patients.腹主动脉钙化对腹膜透析患者的预后价值。
Int J Med Sci. 2013;10(5):617-23. doi: 10.7150/ijms.5773. Epub 2013 Mar 21.
9
Studies on the in vitro and in vivo antiurolithic activity of Holarrhena antidysenterica.止泻木体外及体内抗尿路结石活性的研究。
Urol Res. 2012 Dec;40(6):671-81. doi: 10.1007/s00240-012-0483-1. Epub 2012 May 24.
10
An update on peritoneal dialysis solutions.腹膜透析液的最新进展。
Nat Rev Nephrol. 2012 Feb 21;8(4):224-33. doi: 10.1038/nrneph.2012.13.